These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 17047654)

  • 1. Novel heteroduplex method using small cytology specimens with a remarkably high success rate for analysing EGFR gene mutations with a significant correlation to gefitinib efficacy in non-small-cell lung cancer.
    Oshita F; Matsukuma S; Yoshihara M; Sakuma Y; Ohgane N; Kameda Y; Saito H; Yamada K; Tsuchiya E; Miyagi Y
    Br J Cancer; 2006 Oct; 95(8):1070-5. PubMed ID: 17047654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib.
    Xu JM; Han Y; Duan HQ; Gao EM; Zhang Y; Liu XQ; Zhang JS; Toschi L; Galetta D; Azzariti A; Paradiso A
    J Cancer Res Clin Oncol; 2009 Jun; 135(6):771-82. PubMed ID: 19020901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens.
    Daniele L; Macrì L; Schena M; Dongiovanni D; Bonello L; Armando E; Ciuffreda L; Bertetto O; Bussolati G; Sapino A
    Mol Cancer Ther; 2007 Apr; 6(4):1223-9. PubMed ID: 17406029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
    Fukuoka M; Wu YL; Thongprasert S; Sunpaweravong P; Leong SS; Sriuranpong V; Chao TY; Nakagawa K; Chu DT; Saijo N; Duffield EL; Rukazenkov Y; Speake G; Jiang H; Armour AA; To KF; Yang JC; Mok TS
    J Clin Oncol; 2011 Jul; 29(21):2866-74. PubMed ID: 21670455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations.
    Asahina H; Yamazaki K; Kinoshita I; Sukoh N; Harada M; Yokouchi H; Ishida T; Ogura S; Kojima T; Okamoto Y; Fujita Y; Dosaka-Akita H; Isobe H; Nishimura M
    Br J Cancer; 2006 Oct; 95(8):998-1004. PubMed ID: 17047648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer.
    Zhang XT; Li LY; Mu XL; Cui QC; Chang XY; Song W; Wang SL; Wang MZ; Zhong W; Zhang L
    Ann Oncol; 2005 Aug; 16(8):1334-42. PubMed ID: 15956035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer.
    Pallis AG; Voutsina A; Kalikaki A; Souglakos J; Briasoulis E; Murray S; Koutsopoulos A; Tripaki M; Stathopoulos E; Mavroudis D; Georgoulias V
    Br J Cancer; 2007 Dec; 97(11):1560-6. PubMed ID: 18000506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers.
    Tokumo M; Toyooka S; Kiura K; Shigematsu H; Tomii K; Aoe M; Ichimura K; Tsuda T; Yano M; Tsukuda K; Tabata M; Ueoka H; Tanimoto M; Date H; Gazdar AF; Shimizu N
    Clin Cancer Res; 2005 Feb; 11(3):1167-73. PubMed ID: 15709185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer.
    Zhou Q; Zhang XC; Chen ZH; Yin XL; Yang JJ; Xu CR; Yan HH; Chen HJ; Su J; Zhong WZ; Yang XN; An SJ; Wang BC; Huang YS; Wang Z; Wu YL
    J Clin Oncol; 2011 Aug; 29(24):3316-21. PubMed ID: 21788562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer.
    Sone T; Kasahara K; Kimura H; Nishio K; Mizuguchi M; Nakatsumi Y; Shibata K; Waseda Y; Fujimura M; Nakao S
    Cancer; 2007 May; 109(9):1836-44. PubMed ID: 17387741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA).
    Kimura H; Suminoe M; Kasahara K; Sone T; Araya T; Tamori S; Koizumi F; Nishio K; Miyamoto K; Fujimura M; Nakao S
    Br J Cancer; 2007 Sep; 97(6):778-84. PubMed ID: 17848912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Routine EGFR molecular analysis in non-small-cell lung cancer patients is feasible: exons 18-21 sequencing results of 753 patients and subsequent clinical outcomes.
    Locatelli-Sanchez M; Couraud S; Arpin D; Riou R; Bringuier PP; Souquet PJ
    Lung; 2013 Oct; 191(5):491-9. PubMed ID: 23749122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer.
    Kimura H; Kasahara K; Shibata K; Sone T; Yoshimoto A; Kita T; Ichikawa Y; Waseda Y; Watanabe K; Shiarasaki H; Ishiura Y; Mizuguchi M; Nakatsumi Y; Kashii T; Kobayashi M; Kunitoh H; Tamura T; Nishio K; Fujimura M; Nakao S
    J Thorac Oncol; 2006 Mar; 1(3):260-7. PubMed ID: 17409866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humoral immune responses to EGFR-derived peptides predict progression-free and overall survival of non-small cell lung cancer patients receiving gefitinib.
    Azuma K; Komatsu N; Hattori S; Matsueda S; Kawahara A; Sasada T; Itoh K; Hoshino T
    PLoS One; 2014; 9(1):e86667. PubMed ID: 24497964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer].
    Li J; Qu L; Wei X; Gao H; Wang W; Qin H; Tang C; Guo W; Wang H; Liu X
    Zhongguo Fei Ai Za Zhi; 2012 May; 15(5):299-304. PubMed ID: 22613337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure.
    Cho KM; Keam B; Kim TM; Lee SH; Kim DW; Heo DS
    Korean J Intern Med; 2015 Nov; 30(6):891-8. PubMed ID: 26552465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.
    Paz-Ares L; Tan EH; O'Byrne K; Zhang L; Hirsh V; Boyer M; Yang JC; Mok T; Lee KH; Lu S; Shi Y; Lee DH; Laskin J; Kim DW; Laurie SA; Kölbeck K; Fan J; Dodd N; Märten A; Park K
    Ann Oncol; 2017 Feb; 28(2):270-277. PubMed ID: 28426106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lifestyle risks exposure and response predictor of gefitinib in patients with non-small cell lung cancer.
    Ying H; Yang XD; Sun Z; Ning X; Wang Y; Bai C; Chen S; Wang Y
    Med Oncol; 2014 Oct; 31(10):220. PubMed ID: 25216867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [EGFR gene mutation statuses in advanced non-small cell lung cancer patients and their influence on effect of gefitinib].
    Zhong W; Wang M; Li L; Xia Y; Chen M; Zhang L; Zhao J
    Zhongguo Fei Ai Za Zhi; 2012 Sep; 15(9):513-20. PubMed ID: 22989454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
    Maemondo M; Inoue A; Kobayashi K; Sugawara S; Oizumi S; Isobe H; Gemma A; Harada M; Yoshizawa H; Kinoshita I; Fujita Y; Okinaga S; Hirano H; Yoshimori K; Harada T; Ogura T; Ando M; Miyazawa H; Tanaka T; Saijo Y; Hagiwara K; Morita S; Nukiwa T;
    N Engl J Med; 2010 Jun; 362(25):2380-8. PubMed ID: 20573926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.